Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
A prescription drug's label AE section is almost entirely based on clinicians' impression of patients' symptoms, not the patients' own reports.
Endocrine Cancer News
Sharing health information about an older patient with family may have unintended consequences.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma
- Neutrophil Count May Be Associated with Survival in Localized Prostate Cancer
- Multigene Panel Testing for Breast, Ovarian Cancer Clinically Valuable
- In Fit Patients With NSCLC, Erlotinib Not Recommended
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
- A Decade of Dramatic Change in the Treatment of Prostate Cancer
- Unregulated E-Cigarettes Called Unacceptable by ASCO
- Dasatinib Plus Chemo Achieves Long-Term Remission in Ph+ Acute Leukemia
- Patupilone Shows Activity in Recurrent NSCLC Brain Metastases
- How Many People Does it Take to Increase Colorectal Cancer Screening to 80%?
- The association between obesity and gastrointestinal cancer
- Blood Test May Predict Relapse in Early-Stage Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|